CompletedPhase 2ACTRN12608000379314

Bee venom allergy desensitisation study

A single centre, randomised, controlled Phase 1/2 study of adults with bee venom allergy to evaluate the safety and efficacy of an Advax-adjuvanted bee venom desensitisation regime

Sponsor

Vaxine pty Ltd

Enrollment

60 participants

Start Date

May 1, 2008

Study Type

Interventional

Conditions

Bee venom allergy

Summary

This study will determine the most effective way to administer bee venom desensitisation therapy for people with serious life threatening bee venom allergy

Eligibility

Sex: Both males and femalesMin Age: 18 YearssMax Age: 65 Yearss

Plain Language Summary

Simplified for easier understanding

This study is testing desensitisation therapy for people who are allergic to bee stings. The treatment involves gradually exposing the body to small amounts of bee venom so the immune system learns to tolerate it, reducing the risk of a severe allergic reaction from future stings. It is open to adults aged 18 to 65 with a known bee sting allergy.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Bee venom desensitisation therapy administered per usual outpatient desensitisation therapy regimen involving weekly subcutaneous administrations of bee venom extract (0.001 microgram increasing in s

Bee venom desensitisation therapy administered per usual outpatient desensitisation therapy regimen involving weekly subcutaneous administrations of bee venom extract (0.001 microgram increasing in steps to 0.01, 0.1, 0.3, 1, 3, 6, 10, 15, 20, 25, 30, 35, 40, 45, 50, 70, then 100 microgram as tolerated) formulated with Advax adjuvant 10mg

Locations(1)

The Royal Adelaide Hospital - Adelaide

SA, Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12608000379314